Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas

BACKGROUND: Outcomes in children and adolescents with recurrent or progressive high-grade glioma are poor, with a historical median overall survival of 5.6 months. Pediatric high-grade gliomas are largely immunologically silent or “cold,” with few tumor-infiltrating lymphocytes. Preclinically, pedia...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:N Engl J Med
Päätekijät: Friedman, G.K., Johnston, J.M., Bag, A.K., Bernstock, J.D., Aban, I., Kachurak, K., Nan, L., Kang, K.-D., Totsch, S., Schlappi, C., Martin, A.M., Pastakia, D., McNall-Knapp, R., Farouk Sait, S., Khakoo, Y., Karajannis, M.A., Woodling, K., Palmer, J.D., Osorio, D.S., Leonard, J., Abdelbaki, M.S., Madan-Swain, A., Atkinson, T.P., Whitley, R.J., Fiveash, J.B., Markert, J.M., Gillespie, G.Y.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8284840/
https://ncbi.nlm.nih.gov/pubmed/33838625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa2024947
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia